Compare Allstate Corp (ALL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs DexCom, Inc. — how do they compare? Allstate Corp trades at $254.16 (market cap $64.77B), while DexCom, Inc. trades at $75.82 (market cap $28.93B). The key difference: Allstate Corp is far larger — about 2.2× DexCom, Inc.'s market cap, and Allstate Corp pays a 1.72% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| ALL | DXCM | |
|---|---|---|
Market Cap | $64.77B | $28.93B |
Sector | Financials | Health |
52-Week High | $251.61 | $89.53 |
52-Week Low | $190.00 | $54.84 |
Enterprise Value | $73.56B | $27.89B |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
